Five-Year Results of a Randomized, Single-Center Study of Tacrolimus vs Microemulsion Cyclosporine in Heart Transplant Patients

Tac and mCyA appear to be comparable with regard to 5-year survival, freedom from rejection and CAV. However, compared with mCyA, Tac appears to reduce the adverse effect profile for hypertriglyceridemia and renal dysfunction and the need for hypertensive medications.